Galectin (GALT) CFO Jack Callicutt Executes 10b5-1 Sale of 8,706 Shares
Rhea-AI Filing Summary
Jack W. Callicutt, Chief Financial Officer of Galectin Therapeutics Inc. (GALT), reported transactions on Form 4 showing the exercise and sale of common stock on 09/12/2025. The filing discloses the exercise of 8,706 stock options with an exercise price of $1.37 (options originally granted 01/20/2019 and expiring 01/20/2026). Those 8,706 shares were sold the same day under a Rule 10b5-1 plan adopted April 17, 2025, at a weighted average price of $6.4385 (sales ranged $6.33–$6.68). After these transactions the reporting person beneficially owned 7,614 shares, down from 16,320 prior to the transactions. The filing includes an undertaking to provide per-trade sale details on request.
Positive
- Transactions executed under a Rule 10b5-1 plan, indicating pre-specified trading and compliance procedures
- Clear disclosure of option vesting history and an undertaking to provide per-trade sale details on request
Negative
- Significant reduction in reported direct holdings from 16,320 shares to 7,614 shares following the transactions
- Insider sold shares, which may be interpreted by some investors as reduction of insider ownership
Insights
TL;DR: CFO exercised vested options and sold the newly acquired shares under a pre-established 10b5-1 plan, materially reducing his direct holdings.
The Form 4 shows a routine, structured insider liquidity event: 8,706 options were exercised at $1.37 and the resulting shares were sold at a weighted average of $6.4385. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted April 17, 2025, indicating pre-planned sales rather than opportunistic trades. The reporting owner’s direct beneficial holdings declined from 16,320 to 7,614 shares, a meaningful percentage reduction of his publicly reported stake. For investors, this is a material insider sale but the filing provides standard disclosures and an undertaking to supply trade-level sale prices on request.
TL;DR: Disclosure follows governance best practices by using a 10b5-1 plan and documenting option vesting and sale price ranges.
The filing documents that the sales were made under a Rule 10b5-1 plan adopted earlier in the year, which strengthens the compliance posture by reducing timing concerns about insider information. The filing also explains vesting history for the options (25% on grant date 01/20/2016, remainder monthly over three years) and notes the seller will provide transaction-level prices if requested by regulators or shareholders. These disclosures align with transparent reporting expectations for insider transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 8,706 | $1.37 | $12K |
| Exercise | Common Stock | 8,706 | $1.37 | $12K |
| Sale | Common Stock | 8,706 | $6.4385 | $56K |
Footnotes (1)
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. The shares were sold in multiple transactions at prices ranging from $6.33 to $6.68. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The options vested as follows: 25% on January 20, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period.
